Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2

INTRODUCTION: Guselkumab is a human monoclonal antibody against IL-23 used in the treatment of moderate-to-severe psoriasis. This post-hoc analysis evaluated the efficacy and safety of guselkumab in the Asian subpopulation of VOYAGE 1 and VOYAGE 2 through 5 years. METHODS: The proportions of guselku...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Byung Soo, Jo, Seong Jin, Youn, SangWoong, Reich, Kristian, Saadoun, Carine, Chang, Chia-Ling, Yang, Ya-Wen, Huang, Yu-Huei, Tsai, Tsen-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613179/
https://www.ncbi.nlm.nih.gov/pubmed/37750995
http://dx.doi.org/10.1007/s13555-023-01026-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613179/
https://www.ncbi.nlm.nih.gov/pubmed/37750995
http://dx.doi.org/10.1007/s13555-023-01026-7

Ejemplares similares